INCYTE CORP (INCY) Form 8-K — Oct 29, 2026
Incyte reported Q3 2026 total revenue of $1.56 billion and net sales of $1.32 billion, each up 14% year over year, driven by Opzelura (+36% to $255 million) and Hematology/Oncology (+38% to $235 million), while Jakafi grew 4% to $827 million. The company raised full-year 2026 guidance for Opzelura, Hematology/Oncology and total net sales, now guiding total net sales of $5,210-$5,300 million. GAAP results swung to a net loss of $784.8 million (diluted EPS of -$3.86) versus $424.2 million net income a year ago, driven by a one-time $1.23 billion IPR&D charge from the $1.25 billion Vega Therapeutics acquisition; excluding that charge, GAAP operating income rose 18%.
Key figures
- Revenue
- 1557204000
- Guidance
- FY2026 total net sales raised to $5,210-$5,300M (from $5,130-$5,260M); Opzelura raised to $1,100-$1,120M; Hematology and Oncology raised to $890-$910M; all other categories reaffirmed
- Revenue Yoy
- 14%
- Total Assets
- 7287257000
- Cash Position
- 3854572000
- Jakafi net sales
- $827 million, +4% YoY
- Vega iprd expense
- $1.23 billion one-time charge
- Opzelura net sales
- $255 million, +36% YoY
- Total net sales q3
- $1.32 billion, +14% YoY
- Cms opzelura benefit
- $246 million one-time benefit included in 2026 Opzelura guidance
- Vega acquisition price
- $1.25 billion plus up to $750 million in sales milestones
- Hematology oncology net sales
- $235 million, +38% YoY
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.